SCHEMBL23058985

SCHEMBL23058985

Cc1noc(-c2ccc(C=O)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.61
BRD4 O60885 1/20 0.51
LMNA P02545 1/20 0.50
THRB P10828 1/20 0.50
MAPT P10636 4/20 0.47
TP53 P04637 1/20 0.47
AOC3 Q16853 2/20 0.44
CYP2A6 P11509 1/20 0.42
PARP1 P09874 1/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415305 0.84 ACHE (0.80) ACHELMNATHRBMAPTTP53
SCHEMBL3456771 0.81 NPC1 (0.66) BRD4LMNATHRBMAPTTP53
SCHEMBL6702382 0.80 BRD4 (0.56) ACHEBRD4LMNATHRBMAPT
SCHEMBL29569624 0.80 BRD4 (0.56) ACHEBRD4LMNATHRBMAPT
SCHEMBL5952948 0.79 ACHE (0.71) ACHELMNATHRBMAPTTP53
SCHEMBL3858388 0.77 ACHE (0.69) ACHELMNATHRBMAPTTP53
SCHEMBL21850851 0.77 CNR2 (0.40) ACHEBRD4LMNATHRBMAPT
SCHEMBL400963 0.76 ACHE (0.67) ACHELMNATHRBMAPTTP53
SCHEMBL2645654 0.76 ACHE (0.67) ACHELMNATHRBMAPTTP53
SCHEMBL2310534 0.76 ACHE (0.67) ACHELMNATHRBMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116940562-A Acetamido-phenylbenzamide derivatives and methods of use thereof 希华医药有限公司 2023-10-24 CN disclosed
EP-4225745-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Athenex, Inc. (US) 2023-08-16 EP disclosed
US-20220227765-A1 PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS ADRENAS THERAPEUTICS INC. 2022-07-21 US disclosed
WO-2022076662-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ATHENEX, INC. (US) 2022-04-14 WO disclosed
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Health Hope Pharma Limited (HK) 2022-04-07 US disclosed
WO-2021041539-A2 COMPOUNDS AND METHODS OF USE Ferro Therapeutics, Inc. (US) 2021-03-04 WO disclosed
WO-2021041539-A2 COMPOUNDS AND METHODS OF USE Ferro Therapeutics, Inc. (US) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ABCB1, ABCC1, UGT2B7 ACHE 1867/4885BRD4 3982/4885LMNA 3155/4885
US-20220227765-A1 PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS GPX4, GPX1, AIFM2 ACHE 3752/4885BRD4 116/4885LMNA 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.